|Mr. Gene G. Kinney Ph.D.||Pres, CEO & Director||645.61k||1.43M||48|
|Mr. Tran B. Nguyen M.B.A.||Chief Financial Officer||532.64k||N/A||43|
|Mr. Arthur W. Homan J.D.||Chief Legal Officer||492.24k||614.19k||58|
|Ms. Carol D. Karp||Chief Regulatory Officer||324.49k||N/A||64|
|Ms. Karin L. Walker CPA||Chief Accounting Officer & Controller||N/A||N/A||54|
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinsons disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.
Prothena Corporation plc’s ISS Governance QualityScore as of December 1, 2017 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 4; Compensation: 5.